Purchase this article with an account.
Danielle M. Robertson, W. Matthew Petroll, H. Dwight Cavanagh; The Effect of Nonpreserved Care Solutions on 12 Months of Daily and Extended Silicone Hydrogel Contact Lens Wear. Invest. Ophthalmol. Vis. Sci. 2008;49(1):7-15. doi: https://doi.org/10.1167/iovs.07-0940.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. To determine the effects of nonpreserved care solutions on human corneal epithelium in long-term daily wear (DW) compared with overnight (extended) wear (EW) of hyper–oxygen-permeable silicone hydrogel contact lenses.
methods. This was a prospective, randomized, double-masked, single-center, parallel treatment group clinical trial (NCT 00344643). One hundred twenty-one patients completed the 13 month study: (1) Lotrafilcon A (30 night EW, n = 29; DW, n = 32); (2) Galyfilcon A (DW, n = 20); and (3) Lotrafilcon B (6 night EW, n = 20; DW, n = 21). Irrigation chamber collection of corneal surface cells (OD) and confocal microscopy (OS) were performed at baseline, 1 week; and 1, 3, 6, 9, and 12 months of EW. The main outcome measures were: (1) Pseudomonas aeruginosa (PA) binding to exfoliated corneal surface cells; (2) central epithelial thickness (CET); and (3) epithelial surface cell exfoliation rate (desquamation).
results. DW had no significant effect on CET; there was a decrease in CET with EW that recovered (adapted) over 1 year (Lotrafilcon B, P < 0.05). All lens wear (DW, EW) decreased desquamation with adaptive effects over 1 year (P < 0.001). There was no significant difference in PA binding between lenses or modality of wear.
conclusions. PA binding to corneal epithelial cells is a prerequisite for infection, and no binding indicates no lens-enhanced risk of infection. In contrast to prior studies of preserved lens-care products, the absence of a change in the PA binding data results predict that the risk for PA CTL-keratitis should be similar for daily and extended silicone hydrogel lens wear over 1 year when preservative-free care solutions are used. (ClinicalTrials.gov number, NCT00344643.)
This PDF is available to Subscribers Only